1596. Thinking Locally: Can Unit-Specific Methicillin-Resistant Staphylococcus aureus Screening Augment Stewardship Interventions for Febrile Neutropenia?
Session: Poster Abstract Session: Viruses and Bacteria in Immunocompromised Patients
Friday, October 5, 2018
Room: S Poster Hall

 

Background: Inappropriate IV vancomycin prescribing for febrile neutropenia (FN) is an excellent stewardship target given well-established guidelines specifying indications for its use. As a supplement to an educational initiative with institutional FN guidelines, we conducted methicillin-resistant Staphylococcus aureus (MRSA) colonization screening to estimate its prevalence on our hematology/oncology unit. We hypothesize that MRSA prevalence data can augment existing stewardship efforts to improve IV vancomycin use in FN.

 

Methods:

1) Pre-intervention: we conducted a retrospective chart review of vancomycin receipt for FN on a 32-bed Hematology/Oncology unit, 11/2015-5/2016 (control group)

2) Intervention: in 1/2017, we implemented an institutional FN guideline with recurring education to hematology/oncology providers emphasizing criteria for appropriate vancomycin initiation. Vancomycin audit was again conducted from 2/2017-10/2017 (intervention group). The primary outcome was appropriateness of vancomycin use per guideline indications (chi-squared analysis). Use was considered inappropriate if no guideline indications were met.

3) MRSA screening: cultures were obtained from the nares, axilla and groin on admission and bimonthly for 6 weeks and plated on CHROMagar. Screened patients were followed for 5 months for the occurrence of clinical MRSA infection.   

 

Results: Forty-three of 88 controls were started on vancomycin appropriately versus 60 of 91 intervention group patients (49% vs. 66%, p=0.02). Results of MRSA screening and follow-up for invasive infection are shown in table 1.

Conclusion: Recurring, guideline-focused education can improve appropriateness of vancomycin for FN. High NPV in our study supports the hypothesis that MRSA screening can augment stewardship efforts to reduce vancomycin use when not indicated.

 

Rachel Bartash, MD1, Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA1, Adam Binder, MD2, Kelsie Cowman, MPH1, Carol Sheridan, RN MSN OCN BMTCN3, Yi Guo, PharmD4, Michael Levi, ScD, (D) ABMM5, Wendy Szymczak, PhD5, Philip Gialanella, MS5 and Priya Nori, MD1, (1)Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, (2)Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, (3)Oncology, Montefiore Medical Center, Bronx, NY, (4)Pharmacy, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, (5)Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY

Disclosures:

R. Bartash, None

B. Ostrowsky, None

A. Binder, None

K. Cowman, None

C. Sheridan, None

Y. Guo, None

M. Levi, None

W. Szymczak, None

P. Gialanella, None

P. Nori, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.